Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sweet cravings in Parkinson's: could sugar be a clue?

NCT ID NCT05998772

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at why many people with Parkinson's disease eat more sugary foods. Researchers will give 50 participants a sugary drink or a placebo on different days, then measure blood sugar, insulin, and movement symptoms. The goal is to see if fast-acting sugars temporarily improve motor function or other symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glucose (oral glucose tolerance test)
What this could lead to
If it works, this could explain why some Parkinson's patients crave sweets and whether sugar temporarily improves their symptoms.
What could go wrong
This is a small, early-stage study (50 people) looking at short-term effects only. It won't prove any long-term benefit or treatment for Parkinson's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes Parkinson's Disease patients with and without sweet cravings. Recruitment of patients takes place in the outpatient clinic for movement disorders at the University of Kiel.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Parkinson's Disease, stage Hoehn \& Yahr 1.5-3 * Ability to pause antiparkinsonian medication in the morning without relevant impairment * Capacity to give consent (determined in doubt by two independent neurologists, MOCA ≥18) and written informed consent. * Patients are between 50 and 80 years of age, with exceptions for a maximum of 5 additional patients enrolled per group * For stratification into patients with and without sweet craving, a 3-day dietary protocol should be completed once by the patients * Group I: increased hunger for sweets. * Group II: no increased hunger for sweets. For the stratification into patients with and without increased hunger for sweets, participants are asked to answer the following questions: 1. Do you have sudden attacks of cravings for sweets? 2. Would you say that your consumption of sweet food has increased in recent years? 3. Would you describe your consumption of sugary food as increased or excessive? If one of the questions is answered with yes, participants will be assigned to group I, if all questions are answered with no, participants will be assigned to group II. Exclusion Criteria: * Other significant neurological diseases primarily affecting the central nervous system (e.g., multiple sclerosis) * Diagnosis of diabetes mellitus or prediabetes * Use of medications that affect glucose metabolism, such as antidiabetics, glucocorticoids, ciclosporin, tacrolimus, sirolimus, beta-blockers, thiazide diuretics, beta-2 adrenoreceptor agonists, theophylline, Clozapine, olanzapine, paliperidone, quetiapine, risperidone, tricyclic antidepressants, mirtazapine, mianserin, carbamazepine, gabapentin, pregabalin, valproic acid, lithium, antiretroviral drugs, statins * cardiac or brain pacemakers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nutritional and metabolic diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Nutritional and Metabolic Diseases Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department for Neurology, University of Kiel

    RECRUITING

    Kiel, 24118, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.